ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio, Inc. announced that the first participants have been enrolled in a study that is part of an 800-site master protocol trial for NSCLC. The Lung Cancer Master Protocol trial (Lung-MAP) includes a study of Anktiva™ plus Keytruda versus investigator choice of standard-of-care chemotherapy in patients with NSCLC.